Brief: Alphamab Oncology Says Anbenitamab (Kn026) Granted Designation By NMPA For Her2+ Breast Cancer
14/07/2026 16:17
BRIEF-Alphamab Oncology Says Anbenitamab (Kn026) Granted Designation By NMPA For Her2+ Breast Cancer July 14 (Reuters) - Alphamab Oncology 9966.HK:
ANBENITAMAB (KN026) GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA FOR HER2+ BREAST CANCER
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)